254 related articles for article (PubMed ID: 12882980)
21. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
22. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
[TBL] [Abstract][Full Text] [Related]
23. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I.
Zhang FL; Kirschmeier P; Carr D; James L; Bond RW; Wang L; Patton R; Windsor WT; Syto R; Zhang R; Bishop WR
J Biol Chem; 1997 Apr; 272(15):10232-9. PubMed ID: 9092572
[TBL] [Abstract][Full Text] [Related]
25. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
Vogt A; Qian Y; McGuire TF; Hamilton AD; Sebti SM
Oncogene; 1996 Nov; 13(9):1991-9. PubMed ID: 8934546
[TBL] [Abstract][Full Text] [Related]
26. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
Sun J; Qian Y; Hamilton AD; Sebti SM
Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
[TBL] [Abstract][Full Text] [Related]
27. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
28. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
[TBL] [Abstract][Full Text] [Related]
29. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
30. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
Du W; Lebowitz PF; Prendergast GC
Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
[TBL] [Abstract][Full Text] [Related]
31. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I.
Hicks KA; Hartman HL; Fierke CA
Biochemistry; 2005 Nov; 44(46):15325-33. PubMed ID: 16285736
[TBL] [Abstract][Full Text] [Related]
32. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
[TBL] [Abstract][Full Text] [Related]
33. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells.
Finder JD; Litz JL; Blaskovich MA; McGuire TF; Qian Y; Hamilton AD; Davies P; Sebti SM
J Biol Chem; 1997 May; 272(21):13484-8. PubMed ID: 9153192
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
Mahgoub N; Taylor BR; Gratiot M; Kohl NE; Gibbs JB; Jacks T; Shannon KM
Blood; 1999 Oct; 94(7):2469-76. PubMed ID: 10498620
[TBL] [Abstract][Full Text] [Related]
36. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
37. Ras farnesyltransferase: a new therapeutic target.
Leonard DM
J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
[No Abstract] [Full Text] [Related]
38. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
[TBL] [Abstract][Full Text] [Related]
39. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
40. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
